A+ | A | A- | Skip to main content |

800 years stamp

Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Tuesday, 07 April 2026 12:00 AM EOD	Asian-Paints2187.60	Hind-Unilever2110.20	ITC298.55	Trent3823.40	Larsen-and-Toubro3723.00	M-and-M3006.60	Reliance-Industries1304.65	Tata-Steel198.05	Titan-Company4230.70	SBI1030.30	Bharat-Electron427.75	Kotak-Mah-Bank362.70	Infosys1340.15	Bajaj-Finance855.30	Sun-PharmaInds1718.50	HDFC-Bank772.05	TCS2539.85	ICICI-Bank1246.20	Power-Grid-Corpn295.45	Maruti-Suzuki12799.80	Axis-Bank1250.70	HCL-Technologies1441.40	NTPC369.05	Bharti-Airtel1832.15	Tech-Mahindra1473.35	Adani-Ports1380.85	UltraTech-Cem10929.80	Bajaj-Finserv1685.50	Interglobe-Aviat4268.35	Eternal232.00
15 mins delay SENSEX 74,616.58 [509.73]	1.75 0.08%	27.15 1.30%	3.75 1.27%	-10.30 -0.27%	-5.85 -0.16%	-15.05 -0.50%	-0.10 -0.01%	1.95 0.99%	-13.70 -0.32%	-2.35 -0.23%	0.55 0.13%	2.20 0.61%	34.00 2.60%	4.70 0.55%	24.30 1.43%	0.85 0.11%	66.30 2.68%	14.90 1.21%	0.30 0.10%	112.60 0.89%	5.35 0.43%	38.85 2.77%	2.90 0.79%	39.75 2.22%	22.95 1.58%	-7.20 -0.52%	-21.90 -0.20%	12.00 0.72%	-41.05 -0.95%	-0.25 -0.11%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Alembic Pharmaceuticals climbs on securing USFDA nod for Dapagliflozin tablet

07-Apr-26 14:30Hrs IST

The approved drug is therapeutically equivalent to AstraZeneca's reference listed drug (RLD), Farxiga. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and to improve glycaemic control.

Alembic said it was among the first applicants to file a substantially complete ANDA with a paragraph IV certification for the drug, making it eligible for 180 days of shared generic drug exclusivity.

According to IQVIA, the Dapagliflozin tablets market had an estimated size of $10.49 billion for the 12 months ended December 2025.

The company now has a cumulative total of 235 ANDA approvals from the USFDA, including 217 final approvals and 18 tentative approvals.

Alembic Pharmaceuticals, a vertically integrated research and development company, is engaged in the manufacture and marketing of generic pharmaceutical products across global markets. The company's consolidated net profit fell 3.9% to Rs 132.97 crore despite a 10.8% jump in net sales to Rs 1,876.31 crore in Q3 FY26 over Q3 FY25.

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."

A Muthoot M George Enterprise